Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN Trials

Is statin exposure associated with overall survival and cardiac adverse events in men with advanced prostate cancer treated with apalutamide?This cohort study using individual patient data from 2187 patients in the SPARTAN and TITAN randomized clinical trials found that statin exposure was associated with superior overall survival among all apalutamide-treated patients, although patients receiving statins had a higher risk of grade 3 or greater cardiac adverse events, possibly reflecting their preexisting cardiovascular comorbidity.These findings suggest a possible role of statin exposure in patients with advanced prostate cancer treated with androgen blockade.

Corresponding Authors: Neeraj Agarwal, MD, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Ste 5726, Salt Lake City, UT 84112 (neeraj.agarwal@hci.utah.edu); Soumyajit Roy, MBBS, MSc, Department of Radiation Oncology, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Cleveland, OH 44106 (soumyajit.roy2@uhhospitals.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.